Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I-II Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Trial Profile

A Phase I-II Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs H3B-6545 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors H3 Biomedicine
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Jul 2018 Planned End Date changed from 1 Apr 2019 to 1 Dec 2019.
    • 26 Jul 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top